STERIS plc

Capital Structure and Liquidity STERIS maintains a debt-to-equity ratio of 0.27, indicating a relatively conservative capital structure. The company's liquidity position is characterized as medium risk, with a current ratio of 2.48, suggesting adequate short-term liquidity to cover obligations. However, net cash is negative after subtracting total debt, signaling potential liquidity constraints. ### Profitability and Returns STERIS's return on equity (ROE) is 7.86%, and return on assets (ROA) is 5.31%, both of which are below the industry median for medical equipment and supplies firms. The gross margin of 44.37% (1929.4M gross profit on 4347.5M revenue) is in line with industry norms, but the operating margin of 18.06% (785.0M operating income) suggests room for improvement in cost control relative to peers. ### Segments and Geographic Exposure The Healthcare segment is the largest contributor to revenue, with a focus on sterile processing departments and procedural centers. The AST segment supports medical device and pharmaceutical manufacturers, while the Life Sciences segment serves biopharmaceutical and medical device research and manufacturing. Revenue is primarily concentrated in the United States, with additional exposure to international markets, particularly in Europe. ### Growth Trajectory STERIS's revenue for Q3 2026 is $4.35 billion, with a year-over-year growth rate of 4.5%. The company's outlook for the current fiscal year indicates a continuation of this growth trend, driven by increased demand for medical procedures and efficiency improvements in healthcare operations. The next fiscal year is expected to see a moderate acceleration in revenue growth, supported by ongoing investments in capital expenditures and expansion of sterilization services. ### Risk Factors Key risk factors include liquidity constraints due to negative net cash and potential dilution from new offerings or ATM programs. The company's risk assessment highlights medium dilution risk, with source documents mentioning dilution or offering risk. Additionally, the company faces regulatory risks related to new accounting standards such as ASU 2023-09 and ASU 2024-03, which may increase disclosure requirements and administrative costs. ### Recent Events Recent filings include the adoption of ASU 2023-09 and ASU 2024-03, which will enhance income tax and expense disclosures. These standards are effective for fiscal years beginning after December 15, 2025, and will require additional disclosures in the notes to financial statements. The company also reported a restructuring plan for fiscal 2024-2025, including employee severance and contract termination costs.